Stay updated on FLX475 Dose Escalation Trial in Combination With Pembrolizumab
Sign up to get notified when there's something new on the FLX475 Dose Escalation Trial in Combination With Pembrolizumab page.

Latest updates to the FLX475 Dose Escalation Trial in Combination With Pembrolizumab page
- CheckyesterdayNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedAdded a prominent operating-status notice and a v3.2.0 version tag, replacing the prior v3.1.0 revision.SummaryDifference4%
- Check23 days agoChange DetectedOverall, the page has been updated to a new version (v3.1.0) with the removal of a prior disease reference (Head and neck squamous cell carcinoma).SummaryDifference0.4%
- Check37 days agoChange DetectedUpdated to Revision: v3.0.2 and removed the 'Back to Top' link.SummaryDifference0.2%
- Check44 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, pricing, or availability.SummaryDifference0.2%
- Check52 days agoChange DetectedThe webpage has undergone significant updates, including the addition of new facility names and locations, as well as a comprehensive list of related medical topics and diseases, while removing outdated location references and certain medical terms.SummaryDifference11%
- Check66 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.4%
Stay in the know with updates to FLX475 Dose Escalation Trial in Combination With Pembrolizumab
Enter your email address, and we'll notify you when there's something new on the FLX475 Dose Escalation Trial in Combination With Pembrolizumab page.